An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC

Yael Goldberg*, Rinnat Porat, Inbal Kedar, Chen Shochat, Daliah Galinsky, Tamar Hamburger, Ayala Hubert, Hana Strul, Revital Kariiv, Liat Ben-Avi, Moran Savion, Eli Pikarsky, Dvorah Abeliovich, Dani Bercovich, Israela Lerer, Tamar Peretz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Mutations in DNA mismatch repair genes underlie lynch syndrome (HNPCC). Lynch syndrome resulting from mutations in MSH6 is considered to be attenuated in comparison to that caused by mutations in MLH1 and MSH2, thus more likely to be under diagnosed. In this study we report of a common mutation in the MSH6 gene in Ashkenazi Jews. Genetic counseling and diagnostic workup for HNPCC was conducted in families who attended the high risk clinic for inherited cancer. We identified the mutation c.3984-3987dup in the MSH6 gene in 19 members of four unrelated Ashkenazi families. This mutation results in truncation of the transcript and in loss of expression of the MSH6 protein in tumors. Tumor spectrum among carriers included colon, endometrial, gastric, ovarian, urinary, and breast cancer. All but one family qualified for the Bethesda guidelines and none fulfilled the Amsterdam Criteria. Members of one family also co-inherited the c.6174delT mutation in the BRCA2 gene. The c.3984-3987dup in the MSH6 gene is a mutation leading to HNPCC among Ashkenazi Jews. This is most probably a founder mutation. In contrast to the c.1906G>C founder mutation in the MSH2 gene, tumors tend to occur later in life, and none of the families qualified for the Amsterdam criteria. c.3984-3987dup is responsible for 1/6 of the mutations identified among Ashkenazi HNPCC families in our cohort. Both mutations: c.3984-3987dup and c.1906G>C account for 61% of HNPCC Ashkenazi families in this cohort. These findings are of great importance for counseling, diagnosis, management and surveillance for Ashkenazi families with Lynch syndrome.

Original languageAmerican English
Pages (from-to)141-150
Number of pages10
JournalFamilial Cancer
Issue number2
StatePublished - Jun 2010
Externally publishedYes


  • Ashkenazi
  • BRCA
  • Founder
  • MMR
  • MSH6


Dive into the research topics of 'An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC'. Together they form a unique fingerprint.

Cite this